Literature DB >> 12743333

Modern treatment of acromegaly.

Z Merza1.   

Abstract

Acromegaly is an endocrine disorder characterised by increased morbidity and mortality. It is usually caused by a growth hormone secreting pituitary adenoma and is manifested by a variety of clinical features. Surgery is usually the treatment of choice, however over the last few years, several new methods of treatment have been developed. A recent consensus on the targets for treatment has led to multiple studies being conducted to assess the efficacy of the currently available options. This review examines the evidence for and against these treatments.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12743333      PMCID: PMC1742666          DOI: 10.1136/pmj.79.930.189

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  53 in total

1.  Failure of radiotherapy in acromegaly.

Authors:  R Cozzi; M Barausse; D Asnaghi; D Dallabonzana; S Lodrini; R Attanasio
Journal:  Eur J Endocrinol       Date:  2001-12       Impact factor: 6.664

Review 2.  Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.

Authors:  W M Drake; C Parkinson; G M Besser; P J Trainer
Journal:  Trends Endocrinol Metab       Date:  2001-11       Impact factor: 12.015

3.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

4.  Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.

Authors:  Ph Caron; A Beckers; D R Cullen; M I Goth; B Gutt; P Laurberg; A M Pico; M Valimaki; W Zgliczynski
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

5.  Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.

Authors:  R Cozzi; M Barausse; M Sberna; A Lodrini; A Franzini; G Lasio; R Attanasio
Journal:  Pituitary       Date:  2000-12       Impact factor: 4.107

6.  Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.

Authors:  T Abe; D K Lüdecke
Journal:  Eur J Endocrinol       Date:  2001-08       Impact factor: 6.664

7.  The incidence of cerebrovascular accidents in patients with pituitary adenoma.

Authors:  M Brada; L Burchell; S Ashley; D Traish
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

8.  Successful treatment of resistant acromegaly with a growth hormone receptor antagonist.

Authors:  W M Drake; C Parkinson; S A Akker; J P Monson; G M Besser; P J Trainer
Journal:  Eur J Endocrinol       Date:  2001-10       Impact factor: 6.664

9.  Neuropsychologic impairment in adults with brain tumors.

Authors:  J P Maire; B Coudin; J Guérin; M Caudry
Journal:  Am J Clin Oncol       Date:  1987-04       Impact factor: 2.339

10.  Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.

Authors:  J S Bevan; S L Atkin; A B Atkinson; P-M Bouloux; F Hanna; P E Harris; R A James; M McConnell; G A Roberts; M F Scanlon; P M Stewart; E Teasdale; H E Turner; J A H Wass; J M Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

View more
  4 in total

1.  Acromegaly: surgical results in 548 patients.

Authors:  Cecilia Fernández Mateos; Maria García-Uria; Tomás Lucas Morante; José García-Uría
Journal:  Pituitary       Date:  2017-10       Impact factor: 4.107

Review 2.  Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.

Authors:  Kate McKeage; Susan Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Acromegaly associated with a symptomatic Rathke's cyst.

Authors:  Vishal Gupta; Ashley Grossman; Aneesa Kapadia; Kiran Thorat
Journal:  Indian J Endocrinol Metab       Date:  2011-04

4.  Acromegaly: role of surgery in the therapeutic armamentarium.

Authors:  Gerardo Guinto; Miguel Abdo; Erick Zepeda; Norma Aréchiga; Moisés Mercado
Journal:  Int J Endocrinol       Date:  2012-11-12       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.